Selective Organic Cation Transporters ...
Type de document :
Brevet
Titre :
Selective Organic Cation Transporters Inhibitors For The Treatment Of Depressive Disorders
Auteur(s) :
Gautron, Sophie [Auteur]
Neuroscience Paris Seine [NPS]
Pietrancosta, Nicolas [Auteur]
Neuroscience Paris Seine [NPS]
Laboratoire des biomolécules [LBM UMR 7203]
Acher, Francine [Auteur]
Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques [LCBPT - UMR 8601]
Chausset-Boissarie, Laetitia [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques [LCBPT - UMR 8601]
Neuroscience Paris Seine [NPS]
Pietrancosta, Nicolas [Auteur]
Neuroscience Paris Seine [NPS]
Laboratoire des biomolécules [LBM UMR 7203]
Acher, Francine [Auteur]
Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques [LCBPT - UMR 8601]
Chausset-Boissarie, Laetitia [Auteur]
Miniaturisation pour la Synthèse, l’Analyse et la Protéomique - UAR 3290 [MSAP]
Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques [LCBPT - UMR 8601]
Pays :
France
Date de publication :
2019-01-17
Numéro du brevet :
WO2019012150
Discipline(s) HAL :
Sciences cognitives/Neurosciences
Résumé en anglais : [en]
The invention relates to organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. The invention is also directed to pharmaceutical compositions ...
Lire la suite >The invention relates to organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. The invention is also directed to pharmaceutical compositions comprising such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.Lire moins >
Lire la suite >The invention relates to organic cation transporters (OCTs) inhibitors of Formula (A), as well as their pharmaceutically acceptable tautomers, salts or solvates. The invention is also directed to pharmaceutical compositions comprising such OCTs inhibitor of Formula (A) and their use for treating and/or preventing mood-related disorders such as depressive disorders.Lire moins >
Langue :
Anglais
Source :